Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Arovella Therapeutics Limited ( (AU:ALA) ) is now available.
Arovella Therapeutics showcased new pre-clinical data on its CLDN18.2-directed CAR-iNKT cell therapy for gastric and pancreatic cancers at the ISCT 2026 cell and gene therapy conference in Dublin. The poster, led by company scientist Dr Clinton Heinze and selected for an Elevator Pitch presentation, detailed how these engineered cells effectively kill CLDN18.2-positive tumour cells in vitro.
The company reported that armouring the CLDN18.2 CAR-iNKT cells with its IL-12-TM cytokine technology further boosted cytotoxic activity, supporting development of its solid-tumour candidate ALA-105. Management positioned this progress as complementary to ALA-101, its off-the-shelf CD19-targeting cell therapy, which has U.S. FDA IND clearance and is scheduled to enter a phase 1 trial for CD19+ lymphomas and leukaemias in the third quarter of 2026, underscoring Arovella’s broader push in next-generation cell therapies.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is an Australian biotechnology company developing an invariant natural killer T (iNKT) cell therapy platform for blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CD19-targeting CAR-iNKT cell therapy for CD19-positive lymphomas and leukaemias, while ALA-105 targets CLDN18.2-positive solid tumours using cytokine armouring technology.
Average Trading Volume: 909,114
Technical Sentiment Signal: Sell
Current Market Cap: A$84.61M
For detailed information about ALA stock, go to TipRanks’ Stock Analysis page.